



## **SYMPOSIUM 6: The evolving landscape of biosimilars in the world: Barriers to uptake and priorities for real-world evidence generation**

### **Moderator**

**Nicole Pratt, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia**



Professor Nicole Pratt is the Deputy Director of the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Fellow of the International Society of Pharmacoepidemiology (FISPE). She is an expert in biostatistics specialising in development of methods to study the effects of medicines and medical devices in large linked healthcare datasets.

### **Speakers**

**Nicole Pratt, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia**



Professor Nicole Pratt is the Deputy Director of the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Fellow of the International Society of Pharmacoepidemiology (FISPE). She is an expert in biostatistics specialising in development of methods to study the effects of medicines and medical devices in large linked healthcare datasets.

**Shirley Xue LI, The University of Hong Kong, Hong Kong**



Dr Shirley Li is an Assistant Professor, jointly appointed by the Department of Medicine and the Department of Pharmacology and Pharmacy at HKU. Dr Li's primary research interests lie in health technology assessment (HTA), health economics and real-world outcome (HEOR) research using decision analytic models and routine health records. Dr Li's recent research focuses on biologics utilization and safety, the regional economic burden, the cost-effective solutions for autoimmune diseases, and the development



of outcome-based risk-sharing model for innovative and curative therapies. As a core member of CARE Programme in Hong Kong (COVID-19 Vaccines Adverse Events Response and Evaluation Programme), Dr Li has led and contributed to several territory-wide, population-based vaccine safety assessment, particularly for patients with immunological conditions. Dr Li has published actively in the field of pharmacoepidemiology, HTA and health policy. She has co-authored more than 100 research articles including top-tier specialty journals in Lancet, JAMA and BMJ families.

#### **Debra Rowett, Southern Adelaide Local Health Network, Australia**



Professor Rowett, Discipline Leader Pharmacy, Clinical and Health Sciences, UniSA and Director, Drug and Therapeutics Information Service (DATIS), Southern Adelaide Local Health Network. Debra is the current President of the Council of Pharmacy Schools: Australia and New Zealand. Debra serves on a number of local and state advisory committees including the Drug Utilisation SubCommittee of the Pharmaceutical Benefits Advisory Committee. Her research focuses on actively delivering services which support medicines and therapeutics decision making to optimise the outcomes from medicines and minimise the harms. She is Chief Investigator

on numerous grants including the Commonwealth Department of Health Value in Prescribing Program: Biological Disease Modifying Anti-Rheumatic Drugs (bDMARD). Debra has worked extensively in the area of quality use of medicines, inter-professional practice, health policy and workforce development in Australia and internationally.

#### **Ylenia Ingrasciotta, The University of Messina, Italy**



Ylenia Ingrasciotta is a post-doctoral researcher at University of Verona (Italy). Currently, she is also the CEO of the Academic Spin-Off, called "INSPIRE", at Universities of Messina and Verona. She has been involved in several multi-center pharmacoepidemiology studies using different Italian claims and general practice databases. She's currently actively involved in the coordination of an Italian multiregional project, known as the VALORE project, funded by the Italian Medicines Agency and evaluating the comparative post-marketing benefit-risk profile of biological drugs, both originators and biosimilars, in dermatology, rheumatology, gastroenterology and onco-hematology, using real world data from an Italian network of databases (from 16 Italian regions), active surveillance and clinical registries.